What Is Semaglutide? A Research Overview

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that is widely studied in metabolic and incretin research. The material offered here is sold strictly as a research-use-only (RUO) reference compound — it is not for human or veterinary use, not for consumption, and is not an approved medicine in this form. Semaglutide is separately approved as a prescription drug under brand names such as Ozempic, Wegovy, and Rybelsus, but the research peptide described on this page is not that medicine and is not intended for any therapeutic application.

Quick facts

• Class: GLP-1 receptor agonist (incretin mimetic)
• Research focus: metabolic, incretin, and receptor-signaling research
• Form: lyophilized powder, ≥99% HPLC purity, third-party tested
• Status: research use only — not for human or veterinary use

What is Semaglutide?

Semaglutide is a synthetic peptide analog of human GLP-1, an incretin hormone released by the gut. Structurally it is modified to resist enzymatic breakdown and to extend its circulating half-life relative to native GLP-1, which is why it is described as a long-acting analog in the literature. As a GLP-1 receptor agonist, semaglutide is a reference tool used in laboratory and preclinical studies of the incretin system and GLP-1 receptor signaling. In a research-supply context it is supplied as a lyophilized powder for use by qualified researchers and institutions only — never for human or animal administration.

What does the research show?

In published clinical and preclinical research, semaglutide has been characterized as a selective GLP-1 receptor agonist that activates the GLP-1 receptor, a class B G-protein-coupled receptor. Reviews of the GLP-1 receptor agonist class describe that, in study models, binding to the receptor has been associated with glucose-dependent stimulation of insulin secretion, suppression of glucagon release, and delayed gastric emptying [1][2]. Narrative reviews of semaglutide specifically have summarized its investigation across metabolic and other research areas, including obesity, non-alcoholic steatohepatitis, and neurodegenerative-disease models, while noting that these remain areas of ongoing scientific study [3]. All of these findings are reported as outcomes observed in clinical or preclinical research and do not describe effects of the research material sold here.

Mechanisms studied in the lab

• GLP-1 receptor agonism: selective binding to and activation of the GLP-1 receptor, as characterized in receptor-signaling research.
• Incretin and insulin signaling: glucose-dependent insulin-secretion pathways and glucagon suppression, as studied in pancreatic and metabolic models.
• Gastric emptying: modulation of gastric-emptying rate, a frequently studied endpoint in GLP-1 research.

Research status and safety

The semaglutide offered here is a research-use-only material. It is intended solely for in-vitro and laboratory research conducted by qualified professionals. It is not a drug, supplement, or food, and it is not intended to diagnose, treat, cure, or prevent any disease. It must not be administered to humans or animals or used in any clinical, cosmetic, or household setting. Researchers are responsible for handling, storing, and disposing of the material in accordance with applicable laws, institutional policies, and good laboratory practice. Statements on this page have not been evaluated by the FDA.

Handling

Semaglutide is supplied as a lyophilized (freeze-dried) powder. As with other lyophilized research peptides, it is generally stored cold and protected from light and moisture. For general laboratory technique, see our guide on how to reconstitute a research peptide, and browse related compounds in our GLP research peptides category. View this product here: Semaglutide — research-grade, ≥99% pure, third-party tested.

FAQ

How is semaglutide different from tirzepatide?
Both are studied in incretin research, but they differ in their receptor targets. Semaglutide is characterized in the literature as a single-target GLP-1 receptor agonist, whereas tirzepatide is described as a dual agonist that acts at both the GIP and GLP-1 receptors. Read about tirzepatide. Both are sold here as research-use-only materials and neither is for human use.

Is the semaglutide sold here the same as Ozempic, Wegovy, or Rybelsus?
No. Those are FDA-approved prescription medicines. The material offered here is a research-use-only reference compound and is not an approved drug product, is not formulated or labeled for human use, and must not be used as a substitute for any medicine.

Can I buy this for personal use?
No. This material is sold strictly for laboratory research by qualified researchers and institutions. It is not for human or veterinary use, consumption, or any non-research application.

References

1. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls. 2024. NBK551568
2. Kim HS, Jung CH. Oral Semaglutide, the First Ingestible GLP-1 Receptor Agonist. Int J Mol Sci. 2021;22(18):9936. PMC8470357
3. Mahapatra MK, et al. Therapeutic Potential of Semaglutide: A Narrative Review. Pharm Res. 2022;39(6):1233–1248. PMC9159769

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.